期刊文献+

卡培他滨治疗氟尿嘧啶耐药晚期转移性大肠癌的疗效观察 被引量:2

原文传递
导出
摘要 目的:探讨培他滨治疗氟尿嘧啶(5-Fu)耐药晚期转移性大肠癌的临床效果。方法选取经病理确诊的晚期转移性大肠肠癌患者28例,给予卡培他滨口服治疗,连续口服14 d,停药7 d,每21天为1个周期,评价临床疗效及毒性反应。结果28例患者总有效率为28.57%,平均生存期为10个月。结论应用卡培他滨治疗5-Fu 耐药晚期转移性大肠癌可提高总有效率,延长患者生存时间,提高生存质量。
出处 《中国基层医药》 CAS 2015年第13期2047-2048,共2页 Chinese Journal of Primary Medicine and Pharmacy
  • 相关文献

参考文献14

  • 1陈东升.卡培他滨治疗对氟尿嘧啶耐药的晚期转移性大肠癌的疗效观察[J].齐齐哈尔医学院学报,2009,30(12):1420-1421. 被引量:2
  • 2董振香.希罗达[J].中国新药杂志,2002,11(8):652-653. 被引量:9
  • 3Anonymou S. Efficacy of intravenous continuous infusion of flu- orouracil compared with bolus administration in advanced color- ectal cancer. Meta-analysis Group In Cancer [ J ]. J Clin Oncol, 1998,16( 1 ) :301-308.
  • 4邱国钦,万幼峰,吴晓安,陈建清,洪节约,钟小红,高春玲.卡培他滨用于老年大肠癌患者术后辅助化疗的疗效观察[J].四川肿瘤防治,2007,20(4):277-278. 被引量:3
  • 5Scheithauer W, Mekendrick J, Begbie S, et al. Oral capectabine as an alter native to i. v. 5-f luorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase IU trial [ J ]. Ann Oncol,2003,14(12) :1735-1743.
  • 6De Gramont A, Banzi M, Navarre, et al. Oxaliplation/5-Fu/LV in adjuvant colon cancer: Result of the international randomined MOSAIC trial [ J ]. Proc Am Soc Clin Onco1,2003,22 : 10151.
  • 7Schuellerj, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration to eolorectal patients [ J ]. Cancer Chemother Pharmacol, 2000,45 ( 4 ) : 291- 298.
  • 8高锦秀,吴田,石丽.卡培他滨治疗耐5-Fu的晚期转移性结直肠癌疗效观察及护理[J].临床护理杂志,2007,6(6):75-76. 被引量:3
  • 9Van-Cutsem E, Findlay M, Osterwalder B, et al. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in ad- vanced colorectal cancer: results of a randomized phase II study [ J ]. J Clin Onco1,2000,18 (6) : 1337-1345.
  • 10管忠震,刘冬耕,郁宝铭,吴唯勤,时德,赵瑜,魏于全,邹立群,伍晓汀,庄文,冯奉仪,张频,于世英,熊慧华,付强,郑树,黄建瑾,伍钢,杨传永,孙圣荣,阮庆兰.希罗达一线治疗晚期或复发性结直肠癌[J].中华肿瘤杂志,2004,26(2):119-121. 被引量:72

二级参考文献45

共引文献85

同被引文献18

  • 1曾毅栋,刘志奇.氟尿嘧啶类联合奥沙利铂方案与单药卡培他滨治疗晚期转移性小肠癌的临床疗效对比[J].世界临床医学,2017,11(6):99-99. 被引量:3
  • 2Tone LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012 [ J]. CA Cancer J Clin, 2015,65 ( 2 ) : 87-108.
  • 3Shi L, Zhao J, Lu Q, et al. Initial hepatic artery infusion and sys- temic chemotherapy for asymptomatic colorectal cancer with un- resectable liver metastasis [ J]. Int J Clin Exp Med,2015,8 (1): 1000-1008.
  • 4Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015 [ J ]. CA Cancer J Clin ,2015,65 ( 1 ) :5-29.
  • 5Zhang G, Zhou X, Lin C. Efficacy of chemotherapy plus bevaci- zumab as first-line therapy in patients with metastatic colorectal cancer:a meta-analysis and up-date [ J]. Int J Clin Exp Med, 2015,8 ( 1 ): 1434-1445.
  • 6Liu S, Zheng R,Zhang M,et al. Incidence and mortality of color- ectal cancer in Chirta, 2011 [ J ]. Chin J Cancer Res, 2015,27 ( 1 ) :22-28.
  • 7Zhang C, Wang J, Gu H, et al. Capecitabine plus oxaliplatin com- pared with 5-fluorouracil plus oxaliplatin in metastatic colorectal cancer: Meta-analysis of randomized controlled trials [ J]. Oncol Lett ,2012,3 (4) :831-832.
  • 8Chen YS, Xu SX, Ding YB, et al. Colorectal cancer screening in high-risk populations: a survey of cognition among medical profes- sionals in Jiangsu, China [ J ]. Asian Pac J Cancer Prey, 2014,14 ( 11 ) :6487-6491.
  • 9Petrelli F, Coinu A, Ghilardi M, et al. Efficacy of Oxaliplatin- based chemotherapy + Bevacizumab as first-line treatment for ad- vanced colorectal cancer: a system atic review and pooled analysis of published Trials [ J ]. Am J Clin Oncol,2015,38 (2) :227-233.
  • 10van der Werf A, Blauwhoff-Buskermolen S, Langius JA, et al. The effect of individualized NUTritional Counseling on muscle mass and treatment outcome in patients with metastatic colo colon canc- er undergoing chemotherapy: a randomized controlled trial proto- col[ J]. BMC Cancer, 2015, 15 ( 1 ) : 1092.

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部